Compare Amgen, Inc. (AMGN) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Flux Power Holdings Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Flux Power Holdings Inc trades at $0.75 (market cap $16.65M). The key difference: Amgen, Inc. is far larger — about 11779× Flux Power Holdings Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | FLUX | |
|---|---|---|
Market Cap | $196.12B | $16.65M |
Sector | Health | Utilities |
52-Week High | $388.16 | $6.66 |
52-Week Low | $271.18 | $0.73 |
Enterprise Value | $241.41B | $22.81M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLUX trades at $0.7765, up 0.36% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $6.67 million in 2025, with revenue declining to $51 million in 2026, though it maintains a low P/S ratio of 0.29. Recent news highlights the launch of SkyEMS 3.0 AI software, aiming to boost operational efficiency for fleet customers.
Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and net margins. Investment appeal hinges on revenue stabilization and cost management, but high execution risk and cash flow volatility warrant caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
